FDA Approves FLUOROURACIL — Eugia US LLC

# FDA Approves Fluorouracil IV from Eugia US LLC The FDA has approved Eugia US LLC's intravenous fluorouracil formulation (ANDA 202668), adding another generic option to the competitive oncology market and potentially increasing price pressure on existing suppliers of this widely-used chemotherapy agent. The approval expands treatment accessibility for cancer patients while enabling healthcare systems to leverage additional competitive sourcing for this essential cancer medication.